Cetuximab Sarotalocan Sodium

Phase 2

Cetuximab Sarotalocan Sodium is one of 20 therapeutic programs targeting Lung Non-Small Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lung Non-Small Cell CarcinomaNot yet recruiting

Lung Non-Small Cell CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

20 competitors in Lung Non-Small Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

3 2

Opdivo

Bristol-Myers Squibb

Phase 3

3 3

Tecentriq

Roche

Phase 3

3 4

Taxol

Teva

Phase 3

2 5

Imfinzi

AstraZeneca

Phase 3

2 6

Gemzar

Johnson & Johnson

Phase 3

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

4 8

Alimta

GGynecologic Oncology Group

Phase 3

4 9

Gemzar

GGynecologic Oncology Group

Phase 3

3 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Lung Non-Small Cell Carcinoma

NCT06943664

Clinical

Trials by Indication[1]

Lung Non-Small Cell Carcinoma1 trial

Phase II Trial: Photoimmunotherapy and Anti-PD1 in Patients With Refractory Inoperable and Metastatic Non-Small Cell Lung Cancer

Not yet recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06943664·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cetuximab Sarotalocan Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cetuximab Sarotalocan Sodium. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RRoswell Park Cancer Institute

Cetuximab Sarotalocan Sodium

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Lung Non-Small Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News